English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 28 May 2014, 06:35 HKT/SGT
Share:
    

Source: INC Research, LLC
INC Research Announces Partnership with Society for Clinical Research Sites
Partnership reinforces sites' pivotal role in clinical development, demonstrates Company's on-going commitment to fostering strong site relationships globally

Raleigh, N.C., May 28, 2014 - (ACN Newswire) - INC Research, a leading, global Phase I to IV clinical research organization (CRO), today announced a two-year partnership with the Society for Clinical Research Sites (SCRS), the first and only global trade organization fully dedicated to representing the interests of clinical research sites. The Company will participate as a Global Impact Partner (GIP), the highest level of membership within SCRS. This move further underscores INC's continued focus on and commitment to this key stakeholder group, which plays a pivotal role in bringing new therapies to market.

"We're excited to become an active voice in a community that fully recognizes and supports the critical role of sites in the clinical development process," said INC Research CEO Jamie Macdonald. "Developing and maintaining quality relationships with investigative sites around the world is a critical success factor to accelerating the delivery of new medicines to market. Joining SCRS is one more way INC Research can demonstrate our commitment to sites by actively collaborating with industry stakeholders on initiatives aimed at establishing best site practices."

"SCRS is proud to partner with INC Research," said SCRS President, Christine Pierre. "Collaboration with leading organizations across the clinical research landscape is a pivotal strategic platform for SCRS. This commitment by INC Research speaks to their strong desire to better understand the sites' perspective, hear their voice and grow closer to the core of the research process."

As a Global Impact Partner (GIP), INC will participate on the SCRS Global Impact Board at an executive level. Working in tandem with SCRS' Leadership Council, the Board helps set strategic initiatives for the Society, which advocates, connects, educates, and mentors more than 1,400 sites represented across 22 countries. By providing its members the ability to participate in discussions and decisions, the organization helps to give sites a stronger, more credible voice and a shared purpose within the global clinical research community.

INC Research is focused on connecting customers, sites and patients to improve world health. Ranked the "Top CRO to Work with" in the 2013 CenterWatch Global Investigative Site Relationship Survey of more than 2,000 sites globally, the Company is committed to developing and nurturing deep site relationships that ensure rapid study start-up, smooth study conduct and consistently excellent results. For more information, see our Site Relationships fact sheet. http://bit.ly/1pvZqpc

About SCRS

SCRS is a global trade organization founded in 2012 and represents over 1,400 research sites, including 13,000 Investigators and 12,000 research staff in 22 countries. SCRS' mission is to unify and amplify the voice of the global clinical research site community for site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites, as well as companies that sponsor or support the work conducted at the clinical research sites, will benefit from membership and partnership. Visit www.MySCRS.org.

About INC Research

INC Research is a leading, global full-service clinical research organization (CRO) providing the full range of Phase I to IV clinical development services for the world's pharmaceutical, biotech and medical device industries. As a therapeutically focused CRO, with a Trusted Process(R) delivery methodology, developing the medicines people need is something we take personally. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, investigative sites and patients to accelerate the delivery of new medicines to market to improve world health. We were ranked "Top CRO to Work With" by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 100 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.

LinkedIn: https://www.linkedin.com/company/11776
Twitter: https://twitter.com/INC_Research

Contact:
Lori Dorer, Media +1-513-345-1685

###

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: INC RESEARCH, LLC via Globenewswire

Topic: Business Tieup
Source: INC Research, LLC


https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

INC Research, LLC Related News
Nov 7, 2014 08:50 HKT/SGT
INC Research Announces Pricing of Initial Public Offering
Oct 7, 2014 07:10 HKT/SGT
INC Research Files Registration Statement for Initial Public Offering
Oct 3, 2014 10:30 HKT/SGT
INC Research Demonstrates Continued Dedication to Site Relationships at 2014 SCRS Site Solutions Summit
Oct 2, 2014 07:20 HKT/SGT
INC Research Further Reinforces Commitment to Clinical Research Sites and Patients through Creation of New Leadership Role
Aug 6, 2014 03:30 HKT/SGT
INC Research's Tara Fitzgerald and Judy Swilley Named to Annual PharmaVOICE 100
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575